<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05076734</url>
  </required_header>
  <id_info>
    <org_study_id>Luna IRB LG-002</org_study_id>
    <nct_id>NCT05076734</nct_id>
  </id_info>
  <brief_title>Cell- Based Noninvasive Prenatal Testing (NIPT): Single Cell Prenatal Diagnosis (SCPD)</brief_title>
  <acronym>NIPT &amp; SCPD</acronym>
  <official_title>Technology Development for Noninvasive Prenatal Genetic Diagnosis Using Maternal Peripheral Blood: N o Return of Results -Luna Collection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Luna Genetics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Luna Genetics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the overall study is to develop improved methods for recovery of fetal cells&#xD;
      from the mother's blood in order to develop a clinically useful form of cell-based,&#xD;
      diagnostic, noninvasive prenatal testing (NIPT). Luna Genetics will analyze blood samples&#xD;
      from healthy pregnant women. A phlebotomist will be sent to any location in the United States&#xD;
      to collect the blood sample. Sample identifiers will be removed as the first step so that&#xD;
      laboratory personnel will not see or have access to identifiers. No information will go back&#xD;
      to patients or their physicians.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 12, 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fetal Cell Recovery and genetic analysis</measure>
    <time_frame>2 months</time_frame>
    <description>Outcome 1 is the number of cells identified as fetal by microscopic staining. This can be converted to units based on volume. If 40 mL of blood is collected and f8 cells are designated as fetal based on microscopic staining, the results can be tabulated as follow: So a result is 8 cells are identified as fetal from one blood draw. This equals 0.2 cells identified per mL of maternal blood. If two or fewer cells are obtained, a blood redraw will be requested from the patient.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Redraw for Fetal Cell Recovery and genetic analysis</measure>
    <time_frame>2 months</time_frame>
    <description>Outcome measure 2 is the number of cells that yield high quality next generation sequencing data suitable for determining copy number across the entire genome. So if 4 of the 8 cells above gave high quality data, the outcome would be 4 cells with high quality copy number data from one blood draw which equals 0.10 high quality cell / mL of mother's blood.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Pregnancy Related</condition>
  <arm_group>
    <arm_group_label>Analysis of blood samples from healthy pregnant women</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A phlebotomist will be sent to any location in the United States to collect the blood sample. Sample identifiers will be removed as the first step so that laboratory personnel will not see or have access to identifiers. No information will go back to patients or their physicians.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Redraw for analysis of blood samples from healthy pregnant women</intervention_name>
    <description>If less than two fetal cells are recovered from maternal blood, a redraw is indicated</description>
    <arm_group_label>Analysis of blood samples from healthy pregnant women</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  18years or older&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unavailability of maternal blood sample of at least 30 ml&#xD;
&#xD;
          -  Language barrier (non-English or Spanish speaking and no adequate interpreter)&#xD;
&#xD;
          -  Maternal age of less than 18 years&#xD;
&#xD;
          -  Higher order multiple pregnancy (triplet or greater)&#xD;
&#xD;
          -  Recent exposure to or Active Covid-19&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Females, 18 years and older</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arthur Beaudet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Luna Genetics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>April O' Connor, MS, LCGC</last_name>
    <phone>928-533-2429</phone>
    <email>aoconnor@lunagenetics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bernadette M Wolff, RN,BSN</last_name>
    <phone>346-355-0111</phone>
    <email>bwolff@lunagenetics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Luna Genetics</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>April O'Connor, MS, LCGC</last_name>
      <email>aoconnor@lunagenetics.com</email>
    </contact>
    <investigator>
      <last_name>Arthur Beaudet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 16, 2021</study_first_submitted>
  <study_first_submitted_qc>September 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

